MedTrace Logo

A 4 Week Study of the Safety, Tolerability, and Pharmacodynamics of ShK-186 (Dalazatide) in Active Plaque Psoriasis

NCT02435342 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2015-05-06

No results posted yet for this study

Summary

The primary purpose of this study is to examine safety outcomes in active plaque psoriasis patients after systemic administration of dalazatide. Clinical outcome measures will also be assessed.

Conditions

Interventions

DRUG

dalazatide

Subcutaneous injection twice per week for a total of 9 doses, followed by four weeks of follow-up.

DRUG

placebo

placebo, Subcutaneous injection twice per week for a total of 9 doses

Sponsors & Collaborators

  • Kineta Inc.

    lead INDUSTRY

Principal Investigators

  • Shawn Iadonato, PhD · Kineta Inc.

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2015-03-31
Completion
2015-03-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02435342 on ClinicalTrials.gov